Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/26/2013US8592383 Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
11/26/2013US8592382 Formulations for the oral administration of therapeutic agents and related methods
11/26/2013US8592381 Method for treating rhinitis and sinusitis by rhamnolipids
11/26/2013US8592380 Aerosol foams comprising clindamycin phosphate
11/26/2013US8592371 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
11/26/2013US8592370 Combination of insulin with triazine derivatives
11/26/2013US8592368 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
11/26/2013US8592162 Compositions, methods and kits for repressing virulence in gram positive bacteria
11/26/2013US8592152 Gene detection assay for improving the likelihood of an effective response to an EGFR antagonist cancer therapy
11/26/2013US8591953 Drug carrier and drug carrier kit for inhibiting fibrosis
11/26/2013US8591948 Antifungal compositions with improved bioavailability
11/26/2013US8591946 Modified release compositions comprising tacrolimus
11/26/2013US8591945 Pregelatinized starch in a controlled release formulation
11/26/2013US8591943 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
11/26/2013US8591939 Adhesive preparation containing fentanyl
11/26/2013US8591938 Liquid compositions of calcium acetate
11/26/2013US8591935 Methods and compositions for treating pain comprising a statin
11/26/2013US8591933 Temporal release of growth factors from 3D micro rod scaffolds for tissue regeneration
11/26/2013US8591922 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
11/26/2013US8591919 Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages
11/26/2013US8591917 Ganglioside based vaccine compositions for subcutaneous administration
11/26/2013US8591912 Algae extraction process
11/26/2013US8591902 Antibody binding to lysophosphatidylglucoside, and composition comprising the same
11/26/2013US8591897 Anti-ERBB2 antibody adjuvant therapy
11/26/2013US8591895 Combinations for the treatment of diseases involving cell proliferation
11/26/2013US8591890 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
11/26/2013US8591885 Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
11/26/2013US8591877 Cellulose-based nanoparticles for drug delivery
11/26/2013US8591875 Biodegradable phosphoester polyamines
11/26/2013US8591874 Inhibition of mammalian hair growth
11/26/2013US8591864 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
11/26/2013US8590233 Stacking wall panel system and methods of installation and use
11/26/2013CA2759399C Inhibitors of the renal outer medullary potassium channel
11/26/2013CA2746831C Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
11/26/2013CA2731801C Therapeutic formulations for the treatment of cold and flu-like symptoms
11/26/2013CA2685831C Novel pharmaceutical composition
11/26/2013CA2684999C Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
11/26/2013CA2663584C Composition and method for treating iron deficiency anemia
11/26/2013CA2661892C Gel type enteral nutrient
11/26/2013CA2649736C Heterocyclic compounds as inhibitors of c-fms kinase
11/26/2013CA2645917C Method of preparing a pulverulent composition and product as obtained
11/26/2013CA2643944C Solid dosage form containing a taste masked active agent
11/26/2013CA2612738C Solid pharmaceutical composition comprising (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman
11/26/2013CA2610361C Combination of 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine and a second active agent and use thereof for plasma glucose control
11/26/2013CA2608283C Pharmaceutical compositions with synchronized solubilizer release
11/26/2013CA2603518C Nutrient composition for promoting collagen production
11/26/2013CA2600550C Composition and method for modulating hydrogen ion physiology
11/26/2013CA2593780C The use of alpha-ketoglutarate in the treatment or prophylaxis of neoplastic disease
11/26/2013CA2590961C [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
11/26/2013CA2585615C Dicarboxamide derivatives and their use as factor xa inhibitors
11/26/2013CA2577156C Guanylhydrazone compounds, compositions, methods of making and using
11/26/2013CA2576727C Derivatives of n-(1h-indolyl)-1h-indole-2-carboxamides, their preparation and their application in therapy
11/26/2013CA2567190C Combinations of hyaluronic acid and polyunsaturated fatty acids
11/26/2013CA2565342C Topical application of marine oils to foods
11/26/2013CA2564868C Methods for treating or preventing restenosis and other vascular proliferative disorders
11/26/2013CA2554051C Non-lamellar compositions of dope and p80
11/26/2013CA2549103C Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
11/26/2013CA2541438C The modulation of hyaluronan synthesis and degradation in the treatment of disease
11/26/2013CA2534132C Medicaments for inhalation comprising betamimetics and an anticholinergic
11/26/2013CA2532982C Thienopyridine and furopyridine kinase inhibitors
11/26/2013CA2511538C Immunostimulatory combinations
11/26/2013CA2425072C Wt1 fusion polypeptides and methods for wt1 immunotherapy
11/26/2013CA2378562C Method for producing oligopolysaccharides
11/26/2013CA2221690C Use of methioninase in anti-methionine and anti-homocysteine chemotherapy
11/22/2013CA2788470A1 Novel ni complex and its derivatives, producing method, and the use thereof as antioxidant
11/21/2013WO2013173808A2 Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
11/21/2013WO2013173803A2 Formulations of amoxicillin and clavulanate potassium and methods for using same
11/21/2013WO2013173759A2 Macrocyclic nucleoside phosphoramidate derivatives
11/21/2013WO2013173757A1 Method for treating non-small cell lung cancer
11/21/2013WO2013173720A1 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
11/21/2013WO2013173707A1 Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
11/21/2013WO2013173694A2 A method of restoring endothelial/smooth muscle architecture and cell signaling pathways to sexual organs
11/21/2013WO2013173693A1 Nanoparticles with enhanced entry into cancer cells
11/21/2013WO2013173638A1 Compositions and methods for modulating smn gene family expression
11/21/2013WO2013173637A1 Compositions and methods for modulating gene expression
11/21/2013WO2013173635A1 Compositions and methods for modulating gene expression
11/21/2013WO2013173608A1 Compositions and methods for modulating mecp2 expression
11/21/2013WO2013173605A1 Compositions and methods for modulating pten expression
11/21/2013WO2013173599A1 Compositions and methods for modulating hemoglobin gene family expression
11/21/2013WO2013173598A1 Compositions and methods for modulating atp2a2 expression
11/21/2013WO2013173595A1 Methods to decrease susceptibility to asthmatic bronchoconstriction
11/21/2013WO2013173583A1 Psma inhibitors
11/21/2013WO2013173519A1 Beta-lactamase substrates and methods of their use for the diagnosis of tuberculosis
11/21/2013WO2013173518A1 Inhibitors of bruton's tyrosine kinase
11/21/2013WO2013173506A2 Method of treating muscular degradation
11/21/2013WO2013173492A1 Antiviral compounds with an imidazole - biphenyl - imidazole core
11/21/2013WO2013173488A1 Antiviral compounds inhibitors of hcv ns5b
11/21/2013WO2013173441A2 Enhancer of zeste homolog 2 inhibitors
11/21/2013WO2013173436A1 Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
11/21/2013WO2013173428A1 Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
11/21/2013WO2013173417A2 Glucokinase activator compositions for the treatment of diabetes
11/21/2013WO2013173392A1 Drug-conjugates, conjugation methods, and uses thereof
11/21/2013WO2013173382A1 Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
11/21/2013WO2013173370A1 Small molecule inhibitors of rna binding motif (rbm) proteins for the treatment of acute cellular injury
11/21/2013WO2013173330A1 Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
11/21/2013WO2013173326A1 Methods of using (4s,4as,5ar,12as)-4- dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
11/21/2013WO2013173317A1 TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
11/21/2013WO2013173307A1 Multi-target modulation for treating fibrosis and inflammatory conditions
11/21/2013WO2013173283A1 Dosage regimen for a pi-3 kinase inhibitor
11/21/2013WO2013173254A1 Bicyclic compounds as kinases inhibitors
1 ... 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 ... 7860